What is claimed is:

10

15

- 1. A silyl linker for use in the solid-phase synthesis of nucleic acid, comprised of a compound of the general formula or its ester or salt:
- - 2. The compound according to Claim 1 wherein the spacer moiety (A) is an alkylene group represented by the formula: $-(CH_2)n$ -wherein "n" is a natural number.
 - 3. The compound according to Claim 2 wherein "n" is 2-18.
 - 4. The compound according to Claim 2 or 3 wherein the alkylene group has at least one ether or thioether bond.
 - 5. The compound according to any one of Claims 1 to 4 wherein R1 and R2 are an alkyl group having 1 to 5 carbon atoms.
 - 6. The compound according to any one of Claims 1 to 4 wherein the aryl group of R1 and R2 has a substituent of alkyl, nitro, cyano, halogeno or methoxy group.
- 7. The compound according to any one of Claims 1 to 6 wherein a benzene ring structure has a substituent.
 - 8. The compound according to Claim 7 wherein the substituent of the benzene ring structure is selected from the group consisting of alkyl having 1 to 4 carbon atoms, halogeno, nitro, cyano and methoxy groups.
- 25 9. A 3'-end nucleoside unit having the compound according to any one of Claims 1 to 8 linked via an oxygen atom to the

3-position of a sugar of the nucleoside or its derivative.

- 10. The 3'-end nucleoside unit according to Claim 9 wherein a base constituting the nucleoside is thymine.
- 11. The compound according to Claim 10 which is
- 5'-O-(4,4'-dimethoxytrityl)-thymidine-3'-O-diisopropylsi yl-4-benzoylaminobutanoic acid triethylammonium.
 - 12. A solid-phase support having the 3'-end nucleoside unit according to Claim 9 introduced thereon.
- 13. The solid-phase support according to Claim 12 having the 3'-end nucleoside unit at a ratio of 20-30 μ mol/g.
 - 14. The solid-phase support according to Claim 12 or 13, which is HCP solid-phase support.
 - 15. A method for synthesis of a nucleic acid oligomer with the use of the solid-phase support according Claims 12, 13 or 14.
 - 16. The method according to Claim 15 wherein the nucleic acid oligomer contains a modified base.

20

15